Pharmacological Regulation in the USA and Pharmacokinetics Parameters of Firocoxib, a Highly Selective Cox-2, by Pain Management in Horses.
Abstract: The objective of the study was to conduct a review of the pharmacological regulation and pharmacokinetic parameters of firocoxib when administered orally or intravenously in horses. A search for literature was done in SCOPUS and PubMed for studies that had to evaluate the pharmacological regulation as well as the pharmacokinetic parameters of firocoxib when administered in horses. The nonsteroidal anti-inflammatory drugs have analgesic, anti-inflammatory, antipyretics, and antiendotoxic effects. The newly developed is selective to COX2 characterized by less adverse effects in veterinary patients when administered at the recommended doses and do not exceed the established prescribed time. Firocoxib is authorized by the Food and Drug Administration for the treatment of pain in horses, whereas for humans, there is still no approval. Controversy has arisen because the administration of the same pharmaceutical presentation in horses and dogs has pharmacokinetic differences between animal species. However, special attention must be paid to pharmacokinetic differences between species like in horses and dogs. In the case of the horse, the dosage is 0.1 mg/kg in single dose or up to 14 days in oral paste formulation and can keep maintained on the same concentration for a period of 7-14 days in oral tablet formulation. Thorough knowledge of pharmacological regulations and pharmacokinetic parameters, it allows the posology and effective application of firocoxib in pathologies associated with chronic pain, avoiding the indiscriminate use by owners and in some cases veterinarians, thus reducing the negative impacts on horse's health.
Copyright © 2019 Elsevier Inc. All rights reserved.
Publication Date: 2019-02-21 PubMed ID: 31133314DOI: 10.1016/j.jevs.2019.02.007Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
- Review
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research is centered on assessing the regulatory mechanics and drug action parameters of Firocoxib, a highly selective COX-2 inhibitor, particularly when given orally or intravenously to horses.
Objective and Methodology
- The goal of this study was to review the regulations around the use of firocoxib, and how it interacts within a horse’s body (its pharmacokinetics), when administered orally or intravenously.
- The researchers conducted an extensive literature review, sourcing articles from SCOPUS and PubMed that assessed the drug’s pharmacological regulations and pharmacokinetics.
Findings
- Nonsteroidal anti-inflammatory drugs, such as firocoxib, are found to have analgesic, anti-inflammatory, antipyretic and antiendotoxic effects.
- Firocoxib is designated as highly selective for COX-2, which means this medication targets the COX-2 enzymes responsible for inflammation and pain, reducing the chance of adverse effects in veterinary patients when given at the recommended doses, and not exceeding the established prescribed time.
- The Food and Drug Administration has authorized the use of Firocoxib for pain management in horses, but it is yet to get approval for human use.
Pharmacokinetics and Use in Different Animal Species
- There has been controversy regarding the administration of firocoxib in both horses and dogs, as pharmacokinetic differences have been noted between these two animal species.
- In horses, the dosage of Firocoxib is 0.1 mg/kg in a single dose or up to 14 days in an oral paste formulation, and it can maintain the same concentration for a period of 7-14 days in an oral tablet formulation.
Implications
- A thorough understanding of the pharmacological regulations and pharmacokinetics allow for effective deployment of firocoxib in treating chronic pain-related pathologies.
- This knowledge prevents indiscriminate use by horse-owners and, in some instances, veterinarians, thereby minimizing harmful impacts on the horse’s health.
Cite This Article
APA
Rangel-Nava A, Ramírez-Uribe JM, Recillas-Morales S, Ibancovichi-Camarillo JA, Venebra-Muñoz A, Sánchez-Aparicio P.
(2019).
Pharmacological Regulation in the USA and Pharmacokinetics Parameters of Firocoxib, a Highly Selective Cox-2, by Pain Management in Horses.
J Equine Vet Sci, 77, 36-42.
https://doi.org/10.1016/j.jevs.2019.02.007 Publication
Researcher Affiliations
- Student of Licenciatura en Medicina Veterinaria y Zootecnia, Facultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma del Estado de México, Toluca, México.
- Permited Treating Veterinarian and Official Veterinarian, International Equestrian Federation for Eventing, Endurance and Dresagge, Lausanne, Switzerland.
- Department of Pharmacology, Anaesthesia and Analgesia, Facultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma del Estado de México, Toluca, México.
- Department of Pharmacology, Anaesthesia and Analgesia, Facultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma del Estado de México, Toluca, México.
- Laboratory of Brain Plasticity and Neurobiology of Adiction, Faculty of Science, Universidad Autónoma del Estado de México, Toluca, México.
- Department of Pharmacology, Anaesthesia and Analgesia, Facultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma del Estado de México, Toluca, México. Electronic address: pedrossanchezaparicio0@gmail.com.
MeSH Terms
- 4-Butyrolactone / analogs & derivatives
- 4-Butyrolactone / pharmacokinetics
- Animals
- Cyclooxygenase 2
- Horses
- Pain Management / methods
- Pain Management / veterinary
- Sulfones
- United States
Citations
This article has been cited 6 times.- Shapiro AJ, Kimble B, Hulst F, Herrin KV, Marschner C, Chen CJ, Govendir M. Pharmacokinetic profile of oral firocoxib in the koala (Phascolarctos cinereus). PLoS One 2025;20(9):e0332448.
- Toyoda S, Iizumi K, Yamaguchi J. Metal-catalyzed methylthiolation of chloroarenes and diverse aryl electrophiles. Chem Sci 2025 Jun 25;16(25):11559-11567.
- Buzelato Carli I, Fielding L. Long-Term Firocoxib Use in Horses. J Vet Intern Med 2025 May-Jun;39(3):e70117.
- Ignácio FS, Garcia LV, de Souza GG, Amatti LZ, de Barros LD, Bergfelt DR, Camargo GS, de Meira C, de Almeida BFM. Hematological and Biochemical Effects Associated with Prolonged Administration of the NSAID Firocoxib in Adult Healthy Horses. Vet Sci 2024 Jun 5;11(6).
- Fadel C, Giorgi M. Synopsis of the pharmacokinetics, pharmacodynamics, applications, and safety of firocoxib in horses. Vet Anim Sci 2023 Mar;19:100286.
- Hussen J, Kandeel M, Shawaf T, Al-Mubarak AIA, Al-Humam NA, Almathen F. Immunomodulatory Effects of the Cyclooxygenase Inhibitor Lornoxicam on Phenotype and Function of Camel Blood Leukocytes. Animals (Basel) 2021 Jul 6;11(7).
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists